STOCK TITAN

Procaps Group to Report Second Quarter and First Half 2023 Results and Host Conference Call on Tuesday

(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Tags
conferences earnings
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

MIAMI & BARRANQUILLA, Colombia--(BUSINESS WIRE)-- Procaps Group (NASDAQ: PROC) (“Procaps”), a leading integrated LatAm healthcare and pharmaceutical services company, announced that it will report its results for the second quarter and six months ended June 30, 2023, before market opens on Tuesday, September 5, 2023.

The Company will host a conference call and webcast at 11:00 a.m. Eastern time, on the same day, to discuss the second quarter and first half 2023 results.

To access the call, please use the following information:

Date:

Tuesday, September 5, 2023

Time:

11:00 a.m. ET

Webcast:

Click here to access

Toll Free dial-in number:

1-844-204-8586

Toll/International dial-in number:

1-412-317-6346

Conference ID:

Procaps Group

The conference call will be broadcast live and available for replay at https://bit.ly/45sB21M and via the investor relations section of Procaps’ website here.

A telephone replay will be available approximately two hours after the call and will run through September 12, by dialing 1-877-344-7529 from the U.S., or 1-412-317-0088 from international locations and entering replay pin number: 1873850.

About Procaps Group

Procaps Group, S.A. (“Procaps”) (NASDAQ: PROC) is a leading developer of pharmaceutical and nutraceutical solutions, medicines, and hospital supplies that reach more than 50 countries in all five continents. Procaps has a direct presence in 13 countries in the Americas and more than 5,500 employees working under a sustainable model. Procaps develops, manufactures, and markets over-the-counter (OTC) pharmaceutical products and prescription pharmaceutical drugs (Rx), nutritional supplements and high-potency clinical solutions.

For more information, visit Procaps’ investor relations website investor.procapsgroup.com.

Investor Contact:
Melissa Angelini
ir@procapsgroup.com
investor.procapsgroup.com

Source: Procaps Group, S.A.

Keep reading